Assetmark Inc. Has $111,000 Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Assetmark Inc. boosted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 18.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,808 shares of the company’s stock after purchasing an additional 580 shares during the period. Assetmark Inc.’s holdings in Denali Therapeutics were worth $111,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its position in shares of Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock worth $48,000 after buying an additional 1,847 shares during the last quarter. CWM LLC lifted its position in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after buying an additional 654 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after buying an additional 920 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Denali Therapeutics in the first quarter worth about $147,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Denali Therapeutics in the second quarter worth about $194,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Buying and Selling at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 15,558 shares of Denali Therapeutics stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $29.91, for a total value of $465,339.78. Following the sale, the insider now owns 178,066 shares of the company’s stock, valued at approximately $5,325,954.06. The trade was a 8.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the sale, the director now directly owns 111,056 shares in the company, valued at approximately $3,331,680. This represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,578 shares of company stock valued at $2,474,440 in the last 90 days. 7.90% of the stock is currently owned by company insiders.

Denali Therapeutics Stock Down 12.0 %

DNLI opened at $25.05 on Monday. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33. The company has a fifty day simple moving average of $28.20 and a 200 day simple moving average of $24.09. The stock has a market cap of $3.61 billion, a P/E ratio of -9.08 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the company posted ($0.72) EPS. On average, equities research analysts expect that Denali Therapeutics Inc. will post -2.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Jefferies Financial Group boosted their price target on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Bank of America lifted their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. JPMorgan Chase & Co. dropped their price objective on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Citigroup lifted their price objective on Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research note on Thursday, November 7th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.90.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.